echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Ann Neurol-Early onset vs. late onset myasthenia gravis, what is the difference in genomics?

    Ann Neurol-Early onset vs. late onset myasthenia gravis, what is the difference in genomics?

    • Last Update: 2021-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Myasthenia gravis is an autoimmune immune disease, clinical manifestations of muscle weakness and fatigability


    immunity

    Early-onset (EO) and late-onset (LO) myasthenia gravis have obvious epidemiological and pathological features


    The recent genome-wide association study ( GWAS ) found some genetic risk sites for myasthenia gravis, providing a glimpse into the underlying disease mechanism


    GWAS


    Recently, Lahiru Handunnetthi and others of the University of Oxford developed Priority Index, a genomics method that combines cell-type-specific functional genomic information, such as gene expression and chromatin organization, with the findings of GWAS to determine disease-related Gene


    Developed Priority Index, a genomics method that combines cell type-specific functional genomic information, such as gene expression and chromatin organization, with the findings of GWAS to identify disease-related genes


    It was also found that the regulator of toll-like receptor 4 signaling was only enriched in early-onset disease genes (fold enrichment = 3.


    Two causal genetic variants were found near the CTLA4 gene (rs231770 and rs231735; posterior probability = 0.


    The practical significance of this research is that the disease-related genes discovered in this research are unique resources in many disciplines, including clinicians, scientists, and the pharmaceutical industry


    The disease-related genes discovered in this study are unique resources in many disciplines, including clinicians, scientists, and the pharmaceutical industry .
    The disease-related genes discovered in this study are unique resources in many disciplines, including clinicians, scientists, and the pharmaceutical industry.








    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.